A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors (NCT06307795)
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ANS014004 as a Single Agent in Participants With Locally Advanced or Metastatic Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase 1, first-in-human, open-label, multi-center study with the aim of exploring the safety, tolerability, PK, and preliminary anti-tumor activity of ANS014004 as a single agent in participants with locally advanced or metastatic solid tumors.
Who can join: Review the eligibility criteria below.
Location: University of California, San Diego — San Diego, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (15 Sites)
- University of California, San Diego — San Diego, California
- Sarah Cannon Research Institute — Denver, Colorado
- Advent Health — Orlando, Florida
- Henry Ford Health Cancer — Detroit, Michigan
- NYU Langone Health — New York, New York
- The University of Texas - MD Anderson Cancer Center — Houston, Texas
- NEXT Oncology, Virginia — Fairfax, Virginia
- Swedish Cancer Institute — Seattle, Washington
- BC Cancer Vancouver Centre — Vancouver, British Columbia
- Princess Margaret Cancer Centre — Toronto, Ontario
- Beijing Chest Hospital — Beijing, Beijing Municipality
- Harbin Medical University Cancer Hospital — Harbin, Heilongjiang
- Henan Cancer Hospital — Zhengzhou, Henan
- Shandong Cancer Hospital — Jinan, Shandong
- Shanghai Chest Hospital — Shanghai, Shanghai Municipality
📞 Contact the Study Coordinator
Phone: 8610 84148921
Email: information.center@avistonebio.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Locally Advanced or Metastatic Solid Tumors
- A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors — San Francisco, California
- PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors — Beverly Hills, California
- A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors — Los Angeles, California
- Study of XB010 in Subjects With Solid Tumors — Irvine, California
Explore by condition: All Locally Advanced or Metastatic Solid Tumors clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.